Tropical Pharmacology

Group Leader: Andreas Hougaard Laustsen

We focus our research on the use of antibody discovery and engineering approaches to combat neglected tropical diseases.

In our laboratories, we have state-of-the-art antibody phage display facilities, which we combine with approaches within toxinology, microbiology, and protein engineering and expression to develop affordable biotherapeutics against diseases particularly affecting the developing world.Our flagship project involves the development of the world’s first recombinant snakebite antivenom based on carefully selected mixtures of fully human IgG antibodies.

We strive on making an impact through our science, to venture into unchartered therapeutic territory, and to explore cutting-edge biotechnologies in the development of innovative therapies. Meanwhile, we aim to innovate our platform technologies and bring these innovations into use outside of our own field.

The group is highly collaborative, both internally and internationally, and we welcome new members from around the globe.
Key technologies and scientific disciplines

  • Phage display
  • Antibody engineering
  • Cross-reactivity assessment of antibodies
  • High-density peptide microarray technology
  • Microbiology
  • Synthetic biology
  • Assay development
  • Toxinology


Andreas Hougaard Laustsen-Kiel
DTU Bioengineering
+45 29 88 11 34